Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial Meeting Abstract
| Authors: | de Wit, R.; Kulkarni, G. S.; Uchio, E.; Singer, E. A.; Krieger, L.; Grivas, P.; Bajorin, D.; Seo, H. K.; Mourey, L.; Kamat, A.; Nishiyama, H.; Kapadia, E.; Nam, K.; Frenkl, T.; Balar, A. |
| Abstract Title: | Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy283.073 |
| Language: | English |
| ACCESSION: | WOS:000459277302046 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy283.073 |
| Notes: | Meeting Abstract: 864O -- Appears on page viii304 of the abstract book -- Source: Wos |
